Effective January 1, 2025, patients with Aetna® Medicare Advantage or SilverScript® coverage who have metastatic hormone-sensitive prostate cancer (mHSPC) and are new to NUBEQA® are subject to new prior authorization (PA) criteria. Some patients may be required to step through another medication before a PA for NUBEQA is approved.
Patients with other Aetna plans, including commercial and Medicaid plans, other CVS Caremark® formularies, and plans through other insurance carriers are not affected. Additionally, mHSPC patients already on NUBEQA and patients with non-metastatic castration-resistant prostate cancer are not affected.
To learn more, visit Bayer Access Services.
Posted on 2/4/2025